MPN-associated myelofibrosis (MPN-MF).

Lenalidomide and prednisone for myelofibrosis: Eastern Cooperative Oncology Group (ECOG) phase 2 trial E4903.

Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis.

Detangling fibrosis assessment in MPNs.

Ruxolitinib, a selective JAK1 and JAK2 inhibitor for the treatment of myeloproliferative neoplasms and psoriasis.

Phase1/-2 study of Pomalidomide in myelofibrosis.

Assessing new therapies and their overall impact in myelofibrosis.

New drugs for the treatment of myelofibrosis.

Pomalidomide is active in the treatment of anemia associated with myelofibrosis.

Emerging drugs for the therapy of primary and post essential thrombocythemia, post polycythemia vera myelofibrosis.